Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Scynexis Data Show Brexafemme Prevents VVC Recurrence

Feb 10 2022

• By Joseph Haas

Antibiotic resistant bacteria closeup biofilm — Scynexis's Brexafemme is effective against drug-resistant fungal infections

Related Content

Filing Imminent As Mycovia’s Antifungal Prevents Recurrent Vulvovaginal Candidiasis

Dec 10 2020

Scynexis Will Use Contract Commercial Firm To Market Novel Antifungal

Jun 02 2021

Scynexis Prepares For NDA Filing With Second Phase III Success In VVC

Apr 21 2020

Related Companies

Scynexis, Inc.

Additional Topics

Clinical Trials Drug Approval Standards Business Strategies Research & Development Commercial Infectious Diseases BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.